Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.

Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM.

Cancer. 2012 Sep 15;118(18):4471-7. doi: 10.1002/cncr.27429. Epub 2012 Jan 26.

2.

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.

Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):361-6. doi: 10.1016/j.clml.2011.06.007.

3.

Has there been progress in the treatment of older patients with acute myeloid leukemia?

Erba HP.

Best Pract Res Clin Haematol. 2010 Dec;23(4):495-501. doi: 10.1016/j.beha.2010.09.012. Epub 2010 Nov 1. Review.

PMID:
21130413
4.

Lestaurtinib: a multi-targeted FLT3 inhibitor.

Fathi AT, Levis M.

Expert Rev Hematol. 2009 Feb;2(1):17-26. doi: 10.1586/17474086.2.1.17. Review.

PMID:
21082990
5.

DNMT3A mutations in acute myeloid leukemia.

Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O'Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK.

N Engl J Med. 2010 Dec 16;363(25):2424-33. doi: 10.1056/NEJMoa1005143. Epub 2010 Nov 10.

6.

Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic.

Szotkowski T, Muzik J, Voglova J, Koza V, Maaloufova J, Kozak T, Jarosova M, Michalova K, Zak P, Steinerova K, Vydra J, Lanska M, Katrincsakova B, Sicova K, Pavlik T, Dusek L, Indrak K.

Neoplasma. 2010;57(6):578-89.

PMID:
20845997
7.

Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.

8.

The molecular signature of oncofusion proteins in acute myeloid leukemia.

Martens JH, Stunnenberg HG.

FEBS Lett. 2010 Jun 18;584(12):2662-9. doi: 10.1016/j.febslet.2010.04.002. Epub 2010 Apr 11. Review.

9.

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.

Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma R, Verhoef G, Döhner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German Austrian AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK).

Blood. 2010 Apr 1;115(13):2586-91. doi: 10.1182/blood-2009-10-246470. Epub 2010 Jan 26.

10.

A phase 2 study of vorinostat in acute myeloid leukemia.

Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD; Mayo P2C Phase II Consortium.

Haematologica. 2009 Oct;94(10):1375-82. doi: 10.3324/haematol.2009.009217.

11.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS.

Blood. 2009 Oct 1;114(14):2984-92. doi: 10.1182/blood-2009-05-222034. Epub 2009 Aug 4.

12.

Molecular signatures in acute myeloid leukemia.

Mrózek K, Radmacher MD, Bloomfield CD, Marcucci G.

Curr Opin Hematol. 2009 Mar;16(2):64-9. doi: 10.1097/MOH.0b013e3283257b42. Review.

13.

Acute myelogenous leukemia.

Shipley JL, Butera JN.

Exp Hematol. 2009 Jun;37(6):649-58. doi: 10.1016/j.exphem.2009.04.002. Review.

PMID:
19463767
14.

Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.

Jones CV, Copelan EA.

Future Oncol. 2009 May;5(4):559-68. doi: 10.2217/fon.09.20. Review.

PMID:
19450182
15.

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD.

Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8. Review.

16.

Targeted therapy in acute myeloid leukaemia: current status and future directions.

Stapnes C, Gjertsen BT, Reikvam H, Bruserud Ø.

Expert Opin Investig Drugs. 2009 Apr;18(4):433-55. doi: 10.1517/14728220902787628 . Review.

PMID:
19335274
17.

Acute myelogenous leukemia in older adults.

Klepin HD, Balducci L.

Oncologist. 2009 Mar;14(3):222-32. doi: 10.1634/theoncologist.2008-0224. Epub 2009 Mar 12. Review.

18.

Chemotherapy of acute leukemia in adults.

Thomas X.

Expert Opin Pharmacother. 2009 Feb;10(2):221-37. doi: 10.1517/14656560802618746 . Review.

PMID:
19236195
19.

Optimizing therapy for acute myeloid leukemia.

Kohrt HE, Coutre SE.

J Natl Compr Canc Netw. 2008 Nov;6(10):1003-16. Review.

PMID:
19176198
20.

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM.

Blood. 2009 Feb 19;113(8):1749-55. doi: 10.1182/blood-2008-04-152157. Epub 2008 Dec 15.

Supplemental Content

Support Center